Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer’s disease
This interim analysis represents one of the largest real-world lecanemab cohorts reported globally to date. Although absolute rates are not directly comparable with those from clinical trials, the trends in ARIA distributions across APOE genotypes and infusion-related reactions were comparable to those observed in clinical trials.
Authors
- Kinuyo Koizumi
- Kenta Sumitomo (ORCID: https://orcid.org/0009-0004-1755-9510)
- Yukinori Sakata
- Mika Ishii
- Atsushi Iwata
- Akira Endo
- Weijie Kuang
Institutions
- Tokyo Metropolitan Institute of Gerontology (JP)
- Tokyo Metropolitan Geriatric Hospital (JP)
- Eisai (Japan) (JP)
Publication Details
- Journal
- The Journal of Prevention of Alzheimer s Disease
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.tjpad.2026.100541
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00